Markets
Senseonics Shares Jump 26%; 2026 Sales Forecast Raised
The quarterly net loss widened from $19.5 million to $32.7 million despite approximately 140% year-over-year revenue growth.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
Markets
The quarterly net loss widened from $19.5 million to $32.7 million despite approximately 140% year-over-year revenue growth.
Markets
The battery maker is preserving cash and negotiating with lenders over near-term debt after a sharp revenue decline.
SEC Filings
The holding covers 2,385,094 shares in the defense-services company, whose investment case includes further margin improvement.
SEC Filings
The position covers 3,010,531 common shares, with shared voting authority over 2,938,155 shares.
SEC Filings
Vera's first partial commercial quarter brought $10.3 million in drug sales and a wider net loss.
SEC Filings
Verastem expects October financing and cancer-drug revenue to support operations into the first half of 2028.
Earnings
Liquidia expects to fund its accepted settlement with existing cash and drug sales, without additional capital or operating changes.
Earnings
Insurance reviews and hospital approvals are slowing treatment starts, while management expects steady additions rather than a sales burst.
Earnings
Management emphasized post-injection comfort and plans no repeat study, while lowering its full-year adjusted earnings outlook.
SEC Filings
SSGA Funds Management separately reported 5.4% of the common-stock class; the ownership figures date to September 30.
Earnings
Analysts challenged the longer wait and larger trial as Autolus raised its leukemia therapy sales outlook to at least $150 million.
SEC Filings
The passive holding totaled 19,698,380 shares as of September 30, 2026, with shared voting authority over 14,905,671.